PIVIKTO 200MG+50MG TABLET
Program Overview: NOVARTIS INDIA LTD, is dedicated to helping patients in need of Pivikto 200mg + 50mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 18 strips of Pivikto 200mg+50mg tablet, and you will receive 25 additional Strips of Pivikto 200mg+50mg tablets. Therefore, if eligible, you will have to pay only Rs. 6,11,100 for 43 strips, which is Rs.14,212 per strip.
Eligibility Criteria: To qualify for the Pivikto’s Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Alpelisib 200mg+50mg tablet from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Introduction to Pivikto 200mg+50mg Tablet
Pivikto 200mg + 50mg tablet contains the active constituent Alpelisib. It is an anticancer agent that belongs to the class of medications called PI3K (phosphatidylinositol-3-kinase) inhibitors. It is used in combination with other anticancer medication to treat a certain type of breast cancer that has spread to nearby tissues or other parts of the body in women who have already gone through menopause or in men whose cancer got worse during or after certain other treatments. It is also used to treat those who have certain types of PIK3CA-related overgrowth spectrum (PROS; a genetic condition that causes overgrowth and abnormalities in certain body tissues).
Do not take Pivikto 200mg + 50mg if you are allergic to Alpelisib or other ingredients in the medicine. Inform your physician if you have high levels of sugar in your blood or diabetes, bone disease, symptoms of skin rash, blistering of the lips, eyes, or mouth, skin peeling, fever, and red skin. Report to your doctor if you face any symptoms of rash, itching, hives, breathlessness, shortness of breath, wheezing, cough, low blood pressure, or discoloration of lips, tongue, or skin. This medicine is not recommended to be used in children and in adolescents under 18 years of age.
Uses of Pivikto 200mg+50mg Tablet
- HER2- negative Breast cancer
Therapeutic Effects of Pivikto 200mg+50mg Tablet
Pivikto 200mg + 50mg is a kinase inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-alpha. In breast cancer cell cells, PI3K inhibition by this medicine induces an increase in estrogen receptor transcription. These enzymes help cancer cells to grow and multiply. By blocking their action, it can reduce cancer growth and spread and help destroy cancer cells.
Interaction of Pivikto 200mg+50mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products. Certain medications interact with Pivikto 200mg + 50mg and reduce its effectiveness by causing undesirable side effects.
More Information about Pivikto 200mg+50mg Tablet
- Store the Pivikto 200mg + 50mg at 20°C to 25°C
- Protect the medicine from light and excessive moisture.
- Keep the medicine out of reach of children and pets
- If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
How to consume Pivikto 200mg+50mg Tablet
Your doctor will decide the dose and duration of Pivikto 200mg + 50mg based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, immediately after food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water. If you cannot swallow the tablet, mix the tablets into a glass of water as per doctor advice.
Safety Advices for Pivikto 200mg+50mg Tablet
Pregnancy
Do not take Pivikto 200mg + 50mg if you are pregnant because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting pregnancy, or planning to get pregnant during the treatment. Use effective contraception during the treatment and for 1 week after the last dose.
Breast Feeding
Breastfeeding is not recommended in patients taking Pivikto 200mg + 50mg because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Lungs
It is unknown whether Pivikto 200mg + 50mg can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Pivikto 200mg + 50mg is safe to use in patients with liver problems. There is no need for dose adjustments. Inform your physician if you have any liver disease before initiating the therapy.
Alcohol
It is not known whether it is safe to consume alcohol with Pivikto 200mg + 50mg. Please consult your doctor.
Driving
Pivikto 200mg + 50mg may alter your ability to drive and operate heavy machinery. The treatment may cause tiredness hence avoid activities after taking the medicine.